RIVANNA secured a key regulatory milestone this week, obtaining U.S. Food and Drug Administration 510(k) clearance for its Accuro XV Diagnostic Ultrasound System for musculoskeletal imaging in hospital and clinic settings. The AI-ready platform is built on a conformable 3D volumetric probe and is designed to automate wide field-of-view image acquisition at the point of care.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The clearance follows feasibility data from UVA Health and UT Southwestern, published in the Journal of Emergency Medicine, showing non-physician operators can acquire diagnostic-quality extremity images after roughly one hour of training. This task-shifting potential targets emergency and urgent care workflows, where portable, radiation-free imaging could ease staffing constraints and reduce reliance on traditional radiography.
RIVANNA is concurrently developing AI decision-support modules for Accuro XV, including BoneEnhance for improved bone visualization and CADe/x for automated fracture identification. These capabilities are being trained and validated in an eight-site clinical study, which management views as a foundation for future regulatory submissions and commercial differentiation in fracture care.
The company’s Accuro XV program has also received support from the U.S. Department of Health and Human Services and BARDA under a federal preparedness contract, underscoring its relevance to emergency readiness and mass-casualty planning. Together with a growing patent estate and an FDA-registered, ISO 13485-certified manufacturing facility, these developments signal a broader platform strategy in AI-enabled point-of-care imaging.
Beyond musculoskeletal imaging, RIVANNA advanced its neuraxial anesthesia portfolio by highlighting Accuro 3S, described as the first FDA-cleared, AI-enabled real-time guidance platform for these procedures. At the SOAP 2026 conference, the company reported strong clinician engagement and announced that its Pioneer Partner program is full, with a new cohort of 25 Trailblazer sites entering early access.
These Trailblazer sites are expected to generate real-world outcome data to support broader adoption in obstetric and neuraxial anesthesia and to inform reimbursement and commercialization strategies. RIVANNA is also promoting a neuraxial anesthesia trends newsletter, aiming to position itself as a thought leader in AI-assisted imaging and workflow optimization.
The company’s momentum was further recognized by its nomination for MedTech World’s 2026 North America “MedTech Scale-Up of the Year” award. CEO and co-founder Will Mauldin plans to leverage the West Palm Beach event for meetings with investors and partners, potentially expanding the firm’s network as it scales.
Taken together, RIVANNA’s latest FDA clearance, AI roadmap, structured early-access programs, and industry recognition point to a company transitioning from development to broader commercialization. Execution will depend on clinical uptake, evidence generation, and reimbursement outcomes, but the week’s developments strengthen its position in AI-enabled ultrasound and anesthesia guidance markets.